miR-374a is highly expressed in metastatic breast cancer and it downregulates epithelial markers, such as E-cadherin, and upregulates mesenchymal markers, such as N-cadherin and vimentin, thus promoting EMT. Here, CDH1 is linked to breast carcinoma.